All Updates

All Updates

icon
Filter
Funding
Abata Therapeutics receives an undisclosed amount from Bristol Myers Squibb to accelerate Tregg cell therapy development
Precision Medicine
Aug 15, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Akselos introduces software for FPSO monitoring
Digital Twin
Yesterday
Funding
Operant AI raises USD 10 million in Series A funding to boost runtime protection
Next-gen Cybersecurity
Yesterday
Funding
Aembit raises USD 25 million in Series A funding to advance IAM solutions
Identity & Access Management
Yesterday
Product updates
Saviynt launches Intelligence Suite for identity security
Identity & Access Management
Yesterday
Partnerships
Geographic expansion
FarmWise partners with RDO Equipment Co. to expand AI-powered weeding technology for vegetable growers
Smart Farming
Yesterday
Management news
Alberta Food Security Inc. receives USD 5 million order for indoor farming technology
Vertical Farming
Yesterday
Partnerships
AutoStore enhances microfulfilment offering with new grid capabilities and multi-temperature solution
Logistics Tech
Yesterday
Product updates
OpenAI launches o1, a self-fact-checking AI model
Generative AI Applications
Yesterday
Precision Medicine

Precision Medicine

Aug 15, 2024

Abata Therapeutics receives an undisclosed amount from Bristol Myers Squibb to accelerate Tregg cell therapy development

Funding

  • Abata Therapeutics has received an undisclosed amount as an equity investment from Bristol Myers Squibb.

  • The funds are intended to support the clinical development of Abata's Treg cell therapy products, with the company planning to start clinical trials for its ABA-101 therapy for progressive multiple sclerosis (MS).

  • Abata Therapeutics focuses on developing targeted therapies for autoimmune and inflammatory diseases using regulatory Treg technology. The company’s lead programs include treatments for progressive MS, type 1 diabetes, and inclusion body myositis. Its technology leverages Tregs to infiltrate, disrupt, and suppress inflammation at the disease site, offering targeted delivery.

  • Analyst QuickTake: The ABA-101 therapy for MS received the Investigational New Drug (IND) designation from the US FDA in July 2024 . It is a patient-derived T cell receptor (TCR)-Treg cell therapy created specifically for patients with progressive MS.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.